Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)

NCT ID: NCT05877508

Last Updated: 2025-10-28

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-08-01
• Study Completion Date: 2026-07-31

Brief Summary

Persistent viral infection with viral reservoirs and detection of circulating spike protein after the initial acute illness is one potential pathogenic mechanism for Long COVID. This mechanism may be able to be targeted by SARS-CoV-2 monoclonal antibodies (mAbs). This trial will study the safety and efficacy of AER002 to treat individuals with Long COVID in an adult population.

Detailed Description

The study will enroll approximately 30 participants who meet the World Health Organization (WHO) Long COVID criteria, with Long COVID attributed to a SARS-CoV-2 variant susceptible to AER002. Participants will be enrolled at a single center and randomized 2:1 to receive a SARS-CoV-2 monoclonal antibody (AER002) 1200mg or placebo. Evaluations will take place at baseline and at timepoints up to 1-year post-infusion.

Conditions

Long COVID; Post-Acute Sequela of COVID-19; Post-Acute COVID-19

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

AER002

AER002 1200mg administered once by IV

Group Type: EXPERIMENTAL

AER002

Intervention Type: DRUG

Intravenous infusion of AER002

Placebo

Placebo administered once by IV

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Placebo infusion

Interventions

AER002

Intravenous infusion of AER002

Intervention Type: DRUG

Placebo

Placebo infusion

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Male, female, or transgender ≥18 years of age at Screening.
• History of confirmed acute SARS-CoV-2 infection.
• Long COVID attributed to a SARS-CoV-2 infection with a variant against which AER002 is known to have neutralizing activity (prior to August 15, 2022). Note: While individuals re-infected with SARS-CoV-2 after August 15, 2022 will not be excluded, the SARS-CoV-2 infection after which Long COVID symptoms began must pre-date August 15, 2022.
• At least two symptoms that are new or worsened since the time of SARS-CoV-2 infection, not known to be attributable to another cause upon assessment by the PI. Symptoms must have been present for at least 60 days prior to screening and must be reported to be at least somewhat bothersome.
• Body mass index (BMI) 18 to 50 kilograms/meter squared (kg/m2), inclusive, at the time of screening.
• Participants who are of childbearing potential (CBP) and male participants with sexual partner(s) who are females of CBP must agree to use adequate contraception from study consent through 360 days after dosing.

• Participation in a clinical trial with receipt of an investigational product within 28 days or 5 half-lives (whichever is longer) prior to Day 0.
• Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.

Exclusion Criteria

• Long COVID attributed to a SARS-CoV-2 infection after August 15, 2022.
• Previously received treatment or prophylaxis with a SARS-CoV-2-specific mAb, or plan to receive such treatment before exiting the study.
• Previously received COVID-19 convalescent plasma treatment within 60 days prior to Day 0 or plan to receive such treatment before exiting the study.
• Plans to receive any investigational or approved vaccine or booster for SARS-CoV-2 within 60 days prior to Day 0 or before Day 30 following Day 0.
• Active cardiovascular disease or recent (within 3 months) stroke.
• Recent (within 6 months) or planned major surgery.
• Currently hospitalized or recent (within 1 month) unplanned hospitalization.
• Active Hepatitis Bor C infection .
• Untreated or unstable HIV infection (two or more consecutive plasma HIV RNA values >48 copies/mL in the 6 months prior to screen).
• Severe coagulopathy (international normalized ratio ((INR) >2.0, history of hemophilia).
• Severe anemia (hemoglobin <9 grams/deciliter (g/dL)).
• Moderate or severe immunocompromise, according to the current NIH COVID-19 Treatment Guidelines as of March 6, 2023.
• History of anaphylaxis or hypersensitivity upon receiving IV antibody infusions, any componenets of the intervention, prescription or non-prescription drugs, or food products in the past.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Aerium Therapeutics

UNKNOWN

Sponsor Role: collaborator

Patient-Led Research Collaborative

UNKNOWN

Sponsor Role: collaborator

PolyBio Research Foundation

OTHER

Sponsor Role: collaborator

Michael Peluso, MD

OTHER

Sponsor Role: lead

Responsible Party

Michael Peluso, MD

Assistant Professor, Medicine

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Michael J Peluso, MD

Role: PRINCIPAL_INVESTIGATOR

University of California, San Francisco

Locations

UCSF/Zuckerberg San Francisco General Hospital

San Francisco, California, United States

Countries

United States

References

Peluso MJ, Hanson MR, Deeks SG. Infection-associated chronic conditions: Why Long Covid is our best chance to untangle Osler's web. Sci Transl Med. 2024 Nov 13;16(773):eado2101. doi: 10.1126/scitranslmed.ado2101. Epub 2024 Nov 13.

Reference Type: DERIVED

PMID: 39536121 (View on PubMed)

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

23-38629

Identifier Type: -

Identifier Source: org_study_id